Healthcare -
Biotechnology - NASDAQ - US
$ 5.77
-15.9 %
$ 842 M
Market Cap
-1.64
P/E
1. INTRINSIC VALUE
Balance Sheet
89bio, Inc.
| Current Assets | 476 M |
| Cash & Short-Term Investments | 440 M |
| Receivables | 0 |
| Other Current Assets | 36.5 M |
| Non-Current Assets | 2.24 M |
| Long-Term Investments | 0 |
| PP&E | 1.6 M |
| Other Non-Current Assets | 640 K |
| Current Liabilities | 36.1 M |
| Accounts Payable | 15.4 M |
| Short-Term Debt | 1.45 M |
| Other Current Liabilities | 19.3 M |
| Non-Current Liabilities | 41.8 M |
| Long-Term Debt | 1.09 M |
| Other Non-Current Liabilities | 40.7 M |
EFFICIENCY
Earnings Waterfall
89bio, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 385 M |
| Operating Income | -385 M |
| Other Expenses | -17.6 M |
| Net Income | -367 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
89bio, Inc.
| Net Income | -367 M |
| Depreciation & Amortization | -9.14 M |
| Capital Expenditures | -15 K |
| Stock-Based Compensation | 20.6 M |
| Change in Working Capital | -14.5 M |
| Others | -19.3 M |
| Free Cash Flow | -368 M |
Wall Street Analysts Price Targets
89bio, Inc.
Wall Street analysts predict an average 1-year price target for ETNB of $22 , with forecasts ranging from
a
low of
$12 to a high of $29 .
ETNB Lowest Price Target
Wall Street Target
12 USD
107.97%
ETNB Average Price Target
Wall Street Target
22 USD
281.28%
ETNB Highest Price Target
Wall Street Target
29 USD
402.60%
4. DIVIDEND
ANALYSIS
ETNB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
89bio, Inc.
Sold
0-3 MONTHS
71.1 K USD 1
3-6 MONTHS
227 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
575 K USD 1
Bought
50.1 M USD 2
0-3 MONTHS
206 K USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?
Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
zacks.com
- 1 month ago
89bio to Participate in the Leerink Partners Global Healthcare Conference
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible in the investor section of 89bio's website.
globenewswire.com
- 1 month ago
89bio price target lowered by $8 at H.C. Wainwright, here's why
13 Nov 29 Jan
https://thefly.com
- 1 month ago
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – –The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 vs. Week 26 following discussions with the U.S. Food and Drug Administration (FDA); topline data are now expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $440.0 million as of December 31, 2024; a follow-on offering in the 1Q 2025 resulted in gross proceeds of $287.5 million – SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the fourth quarter and full year ended December 31, 2024, and provided corporate updates.
globenewswire.com
- 1 month ago
Should You Buy 89BIO (ETNB) After Golden Cross?
89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
zacks.com
- 1 month ago
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
- 1 month ago
Insider Buying Surges in February, Especially in These 6 Stocks
In January, the number of notable insider purchases was somewhat muted.
247wallst.com
- 1 month ago
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 163,650 shares of the Company's common stock to seven new employees (the “Inducement Grants”) on January 31, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 1 month ago
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 219.1% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
- 2 months ago
89bio's Pegozafermin Is Now Gaining Momentum
89bio's Pegozafermin Is Now Gaining Momentum
seekingalpha.com
- 2 months ago
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 21,671,428 shares of its common stock at a public offering price per share of $8.75 and, in lieu of common stock to a certain investor, pre-funded warrants to purchase up to 6,900,000 shares of its common stock at a public offering price of $8.749. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. In addition, 89bio has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 4,285,714 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $250.0 million. The offering is expected to close on or about January 30, 2025, subject to the satisfaction of customary closing conditions.
globenewswire.com
- 2 months ago
Why 89bio Stock Lagged the Market Today
89bio (ETNB 0.11%) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a new stock issue.
fool.com
- 2 months ago
8. Profile
Summary
89bio, Inc. ETNB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 842 M
Dividend Yield
0.00%
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Contact
142 Sansome Street, San Francisco, CA, 94104
https://www.89bio.com
IPO
Date
Nov. 11, 2019
Employees
93
Officers
Mr. Shiva K. Natarajan CPA
Senior Vice President of Finance & Principal Accounting Officer
Mr. Francis W. Sarena
Chief Operating Officer
Ms. Amanda Kurihara
Vice President of People & Culture
Dr. Harry Mansbach M.D.
Chief Medical Officer
Mr. Ryan Stephen Martins
Chief Financial Officer
Ms. Melissa Abel
Senior Vice President of Commercial Strategy
Mr. Michael Baldwin
Senior Vice President & Head of Quality
Ms. Annie J. Chang M.B.A.
Vice President of Investor Relations & Corporate Communications
Mr. Rohan Palekar
Chief Executive Officer & Director
Mr. Quoc Le-Nguyen
Chief Technical Officer